Aggreguide A-100 ADP Assay Evaluation

The study is to characterize the AggreGuide ADP Assay's performance.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Platelet Aggregation ADP Blockers

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Juno Research

Houston, Texas, 77036, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

18-75

Exclusion criteria

less than 60 kg
on antiplatelet meds other than aspirin
antiplatelet drugs contraindicated

Treatment and study plan

platelet aggregation measurement

Other

Primary outcomes

Platelet Activity Index (PAI)

Time frame: 1 week

PAI at baseline and after taking ADP blocking antiplatelet drugs.

Sponsors and collaborators

Lead sponsor

Aggredyne, Inc.

Industry

Registry information

Official study title

Pivotal Study of the AggreGuide A-100 Adenosine Diphosphate (ADP) Assay to Evaluate the Effect of ADP Blocking Drugs on Platelet Aggregation on the AggreGuide A-100 Instrument

Important dates

Study start: 2014
Primary completion: 2014
Study completion: 2014
First posted: Apr 14, 2014
Registry last updated: Apr 4, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed